What our research found
The current altRx home page, five product pages, intake entry point, terms, refund policy, telehealth consent, privacy documents, contact page, FDA records, federal provider registry, production AllyRx catalog, and internal affiliate record were checked. No identifying health information, contact detail, payment, or lead was submitted.
Trinity HealthCare Supply, LLC d/b/a altRx is the consumer-facing operator named on the current site and in the FDA warning letter. The terms say altRx supplies nonclinical content, marketing, customer support, and administration. OpenLoop Health, Inc. operates the technology platform, and independent licensed healthcare professionals provide care.
The current footer names OpenLoop Healthcare Partners, PC and affiliated professional practices as the clinical entities. The federal NPI registry lists OpenLoop Healthcare Partners PC as an active organization. An NPI does not by itself verify every individual clinician's licensure or credentialing, so the assigned professional and state license remain patient-specific.
The home page connects its GLP-1 label to compounded semaglutide and its GLP-1 plus GIP label to compounded tirzepatide. Both product pages identify weekly subcutaneous injection from multi-dose vials. No additive, concentration, vial quantity, exact pharmacy, or patient-specific significant difference from a commercially available product is published before intake.
Compounded semaglutide is displayed at $89 per month and compounded tirzepatide at $149 per month. The banner calls these same-price-every-month rates but also says the offer ends September 5 at midnight. They are shown as current promotional recurring prices, not averaged plan rates and not durable leaderboard inputs.
The manufacturer-brand pages display Zepbound at $1,249 per month, Wegovy at $1,579 per month, and Ozempic at $1,149 per month. The terms say a displayed bundled total can include the pharmacy drug charge, professional services, and platform access. Final strength, supply, pharmacy, insurance treatment, savings eligibility, and checkout total still need confirmation.
Zepbound and Wegovy map to exact active AllyRx medication identities. Ozempic remains an unmapped editorial card because the current production catalog does not expose a reusable exact Ozempic identity. Ozempic is an FDA-approved semaglutide product for labeled diabetes and risk-reduction uses, but weight-loss-only prescribing is off label.
No separate membership fee is advertised. Current pages describe the bundled price as covering telehealth consultation, a personalized care plan, medication when clinically appropriate, lab services where applicable, online support, supplies for the compound programs, and shipping. Coverage depends on approval and the selected plan.
The subscription begins when payment is submitted. Current terms permit cancellation up to 48 hours before the monthly processing date, but the newer refund policy requires at least 72 hours before the next billing date. Missing the stricter window allows another nonrefundable charge, so 72 hours is the defensible consumer-facing deadline.
The refund policy says payments are final even when the member does not complete intake, does not attend consultation, does not accept a prescription, or does not use the service. Multi-month and bundled plans are indivisible. There is no refund or credit for unused months, unused services, or undelivered or unshipped medication.
The stated exception is clinician-initiated medical disqualification. Any refund covers the unused portion after deducting the value of provider review, consultation, records, laboratory work, prescriptions, and medication already ordered or shipped. Prescription medications are nonreturnable; damaged or incorrect items may qualify for replacement rather than a refund.
The intake begins with a free two-minute assessment. A licensed provider may review the case asynchronously or by live video under state rules and retains discretion over eligibility and prescribing. The site does not guarantee a prescription, result, or specific rate of weight loss.
The terms state that adults in all 50 states and the District of Columbia may access the service, subject to state-specific provider availability and prescribing authority. Care is cash pay outside federal, state, and private payer programs. The site advertises HSA and FSA use, but eligibility and reimbursement are not guaranteed.
Current pharmacy disclosures name RedRock Pharmacy, Health Warehouse, Precision Medicine, and Triad Rx. A prescription may be filled within the network or sent to a pharmacy of the patient's choice, and network prescriptions may transfer among pharmacies for availability, pricing, or operational reasons.
Shipping is advertised as free and fast, but public timing statements do not fully agree. The FAQ says typical processing and delivery take about four to five business days, while other current surfaces have described different windows. Pharmacy assignment, prescription processing, carrier conditions, and state rules-specific requirements may change actual timing.
The semaglutide page's 56-day room-temperature statement is difficult to reconcile with FDA's current recommendation for multi-dose compounded GLP-1 vials. FDA recommends discarding such a vial within 28 days of first use and warns about refrigeration failures in transit. The label, pharmacy, and treating professional should resolve storage and temperature-excursion questions before dosing.
Support routes include the patient portal, care@altrx.com, and +1 607-601-6969. The site advertises unlimited 24/7 support, while the contact page allows up to 48 hours for general inquiries and labels that channel non-urgent. No universal urgent clinical, billing, pharmacy, or shipment escalation standard is published.
The platform privacy statement says altRx is not a HIPAA covered entity and treats clinical medical information separately. It describes cookies, advertising networks, analytics, targeted advertising, and opt-out rights, honors Global Privacy Control where required, and does not honor Do Not Track. The consumer health data policy also says health data may be shared with third parties to market services.
The privacy documents are not fully aligned on legal identity. The main policy names Trinity Healthcare Supply LLC, while the consumer health data policy names Altrx, Inc. This may be drafting inconsistency rather than a different operator, but the entity receiving a privacy request should be confirmed.
FDA warning letter MARCS-CMS 728236 said earlier website labels could make altRx appear to be the compounder and that clinical-proof wording could imply compounded semaglutide and tirzepatide had been FDA evaluated. Current pages now state that Trinity does not compound drugs, name independent pharmacy partners, and disclose that compounds are not FDA approved.
The public FDA warning-letter database did not show a close-out letter for this matter at the time of research. That absence is not proof that altRx failed to respond, nor does it establish a new violation. The letter and the observable corrections should both remain in the review until FDA publishes a different status.
FDA says compounded GLP-1 drugs are not reviewed before marketing for safety, effectiveness, or quality and should be used only when an individual's medical needs cannot be met by an approved drug. Semaglutide and tirzepatide are not currently on the FDA shortage list, and current law limits regular compounding of products that are essentially copies unless a patient-specific significant difference is documented.
The strongest aspects are visible product identity, named clinical and pharmacy roles, national access, and compact bundled pricing. The weakest are regulatory history, promotional volatility, strict no-refund language, cancellation and privacy-document conflicts, storage wording, and outcome-heavy marketing.
- Current compounded prices are $89/mo for semaglutide and $149/mo for tirzepatide under an enrollment promotion ending September 5.
- No monthly average is calculated because each product has one published recurring monthly price.
- The newer 72-hour cancellation rule is stricter than the 48-hour rule in the terms.
- FDA warning letter MARCS-CMS 728236 remains material even though current pages now carry clearer compound and operator disclosures.
- The semaglutide page's 56-day opened-vial storage statement conflicts with FDA's current 28-day recommendation for multi-dose compounded GLP-1 vials.
- Multi-month plans provide no refund for unused months or undelivered or unshipped medication except under a narrow medical-disqualification process.
